These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 8076268)

  • 1. Markers of disease activity in systemic sclerosis.
    Matucci-Cerinic M; Pignone A; Biagini M; Lotti T
    Clin Dermatol; 1994; 12(2):291-7. PubMed ID: 8076268
    [No Abstract]   [Full Text] [Related]  

  • 2. Non organ based laboratory markers in systemic sclerosis.
    McHugh NJ; Distler O; Giacomelli R; Riemekasten G
    Clin Exp Rheumatol; 2003; 21(3 Suppl 29):S32-8. PubMed ID: 12889220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased spontaneous production of interleukin-1 together with inhibitory activity in systemic sclerosis.
    Westacott CI; Whicher JT; Hutton CW; Dieppe PA
    Clin Sci (Lond); 1988 Dec; 75(6):561-7. PubMed ID: 3264777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated serum interleukin-27 levels in patients with systemic sclerosis: association with T cell, B cell and fibroblast activation.
    Yoshizaki A; Yanaba K; Iwata Y; Komura K; Ogawa A; Muroi E; Ogawa F; Takenaka M; Shimizu K; Hasegawa M; Fujimoto M; Sato S
    Ann Rheum Dis; 2011 Jan; 70(1):194-200. PubMed ID: 20705635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [CXCL4: a new biomarker of diagnosis and severity in systemic sclerosis?].
    Marie I
    Rev Med Interne; 2015 Feb; 36(2):69-72. PubMed ID: 25458865
    [No Abstract]   [Full Text] [Related]  

  • 6. [Is there a place of multiantigenes immunodot determination in systemic sclerosis patients without anti-centromeres or anti-Scl70 antibodies?].
    Sautereau N; Gabsi A; Daumas A; Bardin N; Granel B
    Presse Med; 2015 May; 44(5):547-9. PubMed ID: 25813097
    [No Abstract]   [Full Text] [Related]  

  • 7. The pleomorphism of systemic sclerosis: are we ready for 'personalized medicine' in scleroderma?
    Steen VD
    Expert Rev Clin Immunol; 2011 Jul; 7(4):403-5. PubMed ID: 21790281
    [No Abstract]   [Full Text] [Related]  

  • 8. Serum free light chains of immunoglobulins as biomarkers for systemic sclerosis characteristics, activity and severity.
    Lanteri A; Sobanski V; Langlois C; Lefèvre G; Hauspie C; Sanges S; Lambert M; Morell-Dubois S; Hatron PY; Hachulla E; Launay D; Dubucquoi S
    Autoimmun Rev; 2014 Sep; 13(9):974-80. PubMed ID: 25067821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in circulating monocytes in patients with progressive systemic sclerosis.
    Andrews BS; Friou GJ; Berman MA; Sandborg CI; Mirick GR; Cesario TC
    J Rheumatol; 1987 Oct; 14(5):930-5. PubMed ID: 3501471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How useful are serum autoantibodies in the diagnosis and prognosis of systemic sclerosis?
    Meyer O
    Clin Rheumatol; 1998; 17(3):179-80. PubMed ID: 9694047
    [No Abstract]   [Full Text] [Related]  

  • 11. Reduced type I collagen gene expression by skin fibroblasts of patients with systemic sclerosis after one treatment course with rituximab.
    Fraticelli P; De Vita S; Franzolini N; Svegliati S; Scott CA; Tonnini C; Spadoni T; Gabrielli B; Pomponio G; Moroncini G; Gabrielli A
    Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S160-7. PubMed ID: 26339895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of lymphocyte responsiveness to scleroderma-inducing glycosaminoglycan-associated antigen in systemic scleroderma.
    Tamura T; Ishikawa H
    Dermatologica; 1985; 171(6):435-41. PubMed ID: 4092798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Function of monocytes in patients with systemic sclerosis.
    Czirják L; Dankó K; Zeher M; Lukács K; Szegedi G
    Acta Med Hung; 1988; 45(1):53-61. PubMed ID: 3045745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Adhesion molecules in systemic scleroderma].
    Alekperov RT; Timchenko AV; Nasonov EL
    Ter Arkh; 2003; 75(5):91-5. PubMed ID: 12847909
    [No Abstract]   [Full Text] [Related]  

  • 15. Immunologic enhancement of collagen accumulation in progressive systemic sclerosis (PSS).
    Cathcart MK; Krakauer RS
    Clin Immunol Immunopathol; 1981 Oct; 21(1):128-33. PubMed ID: 7273486
    [No Abstract]   [Full Text] [Related]  

  • 16. Connective tissue diseases: New criteria improve recognition of early systemic sclerosis.
    Asano Y; Sato S
    Nat Rev Rheumatol; 2015 Jan; 11(1):3-4. PubMed ID: 25385415
    [No Abstract]   [Full Text] [Related]  

  • 17. DNA topoisomerase I binding to fibroblasts induces monocyte adhesion and activation in the presence of anti-topoisomerase I autoantibodies from systemic sclerosis patients.
    Hénault J; Robitaille G; Senécal JL; Raymond Y
    Arthritis Rheum; 2006 Mar; 54(3):963-73. PubMed ID: 16508979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive value of antinuclear autoantibodies: the lessons of the systemic sclerosis autoantibodies.
    Koenig M; Dieudé M; Senécal JL
    Autoimmun Rev; 2008 Sep; 7(8):588-93. PubMed ID: 18617021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Anti-Scl-70 and anti-centromere autoantibodies. Biological markers of 2 forms of systemic scleroderma].
    Johanet C; Agostini MM; Vayssairat M; Abuaf N
    Presse Med; 1989 Feb; 18(5):207-11. PubMed ID: 2522207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lymphocytotoxic and phagocytotoxic activity in progressive systemic sclerosis.
    Pruzanski W; Lee P; Willshire A; Gladman D; Keystone EC
    J Rheumatol; 1983 Feb; 10(1):55-60. PubMed ID: 6842486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.